- Succeeding with combination products
- Accelerating and assuring clinical trials
- Develop new drug modalities
Cocktails and Conversation with Arthur D. Little at the 42nd J.P. Morgan Healthcare Conference
RELAX, MIX WITH COLLEAGUES, AND ENJOY COCKTAILS ON US
Join Arthur D. Little's healthcare and life sciences experts for an evening of informal conversations about combination products, clinical trial assurance and acceleration and development of new drug modalities. You'll enjoy a locally sourced, sustainable farmed organic menu designed by Chef Michele Ledoux, and cocktails featuring an extensive collection of spirits, craft beers and California wines.
The event will take place in a central location conveniently close to the J.P. Morgan conference. The venue information will be shared once your event registration is confirmed.
ARTHUR D. LITTLE’S HEALTHCARE AND LIFE SCIENCES TEAM
CONVERSATION AND NETWORKING
Arthur D. Little’s healthcare and life sciences experts look forward to talking with you about recent industry trends and the impact on investments, such as:
Succeeding with combination products
Combination products are revolutionizing patient care by merging diverse therapeutic modalities. By incorporating drugs, devices, or biological components, these groundbreaking products can improve efficacy, increase patient compliance, and streamline healthcare delivery for those with complex medical conditions and intricate care requirements. However, the numerous inherent challenges in bringing these products to market have slowed their development, necessitating more active stakeholder engagement for a growth-building ecosystem.
Join us and delve into the multidisciplinary nature of these products and discuss the crucial factors for market entry success, such as regulatory expertise, cross-disciplinary collaboration, seamless technology integration, strategic alliances, and well-planned market access strategies.
Accelerating and assuring clinical trials
Ensuring the timely completion of clinical trials is of utmost importance to both patients and trial sponsors. Nevertheless, frequent delays often result in significant financial losses, missed revenue opportunities, and lost market potential. Although this issue has persisted for some time, we believe that a new perspective is necessary to identify inventive solutions and data-based interventions that pinpoint the most effective strategies for addressing clinical trial obstacles, such as locating suitable sites and recruiting and retaining patients.
Join us to learn about our work in accelerating clinical trials, even in complex and rare disease areas with novel therapeutics.
Developing new drug modalities
Innovative drug modalities such as biologics and gene therapies have shifted the traditional small molecule drug development landscape. While holding promise for patients and companies, these therapeutics pose multifaceted challenges.
Join us as we navigate development risks, address upfront investment requirements, explore the reevaluation of clinical trial methodologies, delve into emerging regulatory issues, and examine new pricing and reimbursement models.
We invite you to a lively discussion around these transformative drug modalities with our team of experts and global industry leaders. Join us as we collectively address challenges and chart a course toward the future of pharmaceutical innovation.
VIEWPOINTS FROM ARTHUR D. LITTLE HEALTHCARE & LIFE SCIENCES
Read Arthur D. Little’s recent report on current and future transformation in healthcare, and the effect these far-reaching changes will have on the life sciences and insurance sectors.
Read Arthur D. Littles perspective of the new speed of innovation in the healthcare area, recently showcased during the recent successful rapid development and rollout of multiple COVID-19 vaccines.
STILL HAVE QUESTIONS? GET IN TOUCH
<div style="text-align: center; font-size:22px"> Form submitted. Thank you! </div>
